A novel assay to detect strand-specific DNA repair after cellular exposure to cisplatin at ICso levels, is used to measure rapid repair in the divergent upstream gene (DUG), a human MutS homolog, and in the bidirectional promoter for dihydrofolate reductase gene (DHFR) and the contiguous upstream DUG. Single-stranded DNA capable of hybridizing to gene-specific probes is generated enzymatically by the 3'-5' exonuclease activity of T4 DNA polymerase. The presence of cisplatin lesions inhibit the exonudeolytic activity of T4 DNA polymerase and block the formation of single-stranded DNA. This decreases the amount of complementary sequence produced when assayed by gene-specific probe hybridization. With the progression of repair, increasing quantities of singlestranded DNA become available for probe hybridization. This assay was applied to human A2780 ovarian carcinoma cells treated with cisplatin at the beginning of G1 phase. A doseresponse experiment showed that the assay was applicable down to cisplatin concentrations of 2.5 SM. To assay for strand-specific gene repair, the synchronized cells were treated with cispatin and then allowed time to repair in drug-free medium. Extensive removal of cisplatin lesions after 2 hr of cellular repair during early G, phase in the DUG and the DUG/DHFR promoter was measured, with no evidence of repair in the unexpressed 6-globin gene. The extent of preferential DNA repair was much more distinct than has been observed previously at high-drug dosage in asynchronous cells.
DUG/DHFR promoter was measured, with no evidence of repair in the unexpressed 6-globin gene. The extent of preferential DNA repair was much more distinct than has been observed previously at high-drug dosage in asynchronous cells.
DNA repair processes are essential for removing lesions from the genome, and it is now recognized that a gene's repair and transcription can be coupled (reviewed in ref. 1) . Cisplatin is a chemotherapeutic agent used in the treatment of a variety of human cancers (2) , where its clinical efficacy appears to involve the formation of DNA lesions (3) (4) (5) that significantly distort the structure of the double helix and, by doing so, potentiate the effect of the drug on tumor cells (6, 7) . The failure of patients to respond to cisplatin chemotherapy is often accompanied by an acquired resistance to the drug (8) . Understanding the biochemical mechanisms by which cisplatin is toxic to tumor cells at doses that normal cells can withstand is of particular clinical interest.
In this study a sensitive assay to measure strand-specific gene repair is used, with cisplatin as the damaging agent. This methodology should be applicable to a broad variety of agents that can modify DNA and arrest the exonucleolytic activity of T4 DNA polymerase. Previous studies with Maxam and Gilbert sequencing have shown that the exonucleolytic progression of T4 DNA polymerase is blocked by bulky lesions such as UV photoproducts (9) and psoralen interstrand crosslinks (10) . The ability of cisplatin-DNA adducts to block the synthetic activity of Thermus aquaticus (Taq) polymerase has recently been exploited in discerning PCR amplification products to measure gene-specific repair (11, 12) . A drawback to this approach is that the PCR-based assays are not yet appropriate for evaluating strand-biased DNA repair and are difficult to quantitate. Here the exonucleolytic activity of T4 DNA polymerase is used to hydrolyze DNA free of cisplatin lesions (13) , allowing the resulting single-stranded DNA sequences to be quantitated by genespecific probe hybridization.
Currently, the most widely used assay for gene-specific repair of cisplatin and other DNA lesions involves the treatment ofpurified genomic DNA with a repair enzyme that creates a strand break at the site of an adduct, followed by alkaline gel electrophoresis and Southern blot hybridization (14, 15) . Although this technique has many advantages, it is necessary to use fairly high doses of DNA-damaging agents to reach detectability. When used to measure repair of intrastrand adducts in human A2780 ovarian carcinoma cells, a cisplatin dose of 200 uM was required (16), compared with the IC50 level of 3 ILM (17) .
In the present study, repair during early G1 phase in the unexpressed 8-globin gene was compared to that in the "divergent upstream gene" [DUG; upstream of the gene encoding dihydrofolate reductase (DHFR), EC 1.5.1.3] and the DUG/DHFR gene promoter. The DUG and DHFR genes are contiguous, and their expression is regulated by a bidirectional promoter with common sequence elements (18) . The DHFR gene is involved in nucleotide synthesis, whereas DUG, which is transcribed in the opposite (divergent) direction, has significant homology to the bacterial mutS and yeast MSH3 DNA mismatch repair genes (18) (19) (20) (23), after which 1 unit of phage T4 DNA polymerase (Boehringer Mannheim) was added. This DNA was slot-blotted onto a charged nylon membrane (Sure Blot, Oncor), which was baked for 2 hr at 80TC. While nylon membrane is routinely used to bind both double-and single-stranded DNA (24) , we confirmed that the membranes used in these experiments bound both molecular species equally.
Probes. In the region ofthe human DUG/DHFR locus, the HindIII restriction enzyme produces a 22-kilobase-pair (kb) fragment containing the 1.8-kb probe sequence that corresponds to the bidirectional promoter of the DUG/DHFR locus (18, 25) . The probe is located 5.5 kb 5' to the HindIll cut site, and transcripts from DUG originate in this region (18) . In the region of the nontranscribed 8-globin gene, the HindIII restriction enzyme produces an 18-kb fragment containing the 2.2-kb probe sequence. The 6-globin probe is located 2 kb 5' to a HindIII cut site. In initial experiments to calibrate the T4 DNA polymerase assay, a probe corresponding to the 1503-bp Kpn I restriction fragment ofphage A DNA was isolated as a band after agarose gel electrophoresis and purified by phenol/chloroform extraction (23) . Probes were labeled for the Genius system (Boehringer Mannheim) chemiluminescent detection with the Klenow enzyme. Hybridization, washes, and detection protocols were carried out as recommended by the manufacturer (Boehringer Mannheim).
Densitometry and Data Analysis. Quantitation of exposed films was carried out by using a Personal Densitometer (Molecular Dynamics). Background-corrected volume integration was performed on individual slot-blot bands. Statistical tests of significance were performed with SPSS-5.0 (SPSS, Chicago) software.
RESULTS
Principles of the T4 DNA Polymerase Assay of Gene-Specific Repair. A schematic representation of the assay is presented in Fig. 1 . Immediately after cellular exposure to cisplatin, the genomic DNA contains a random distribution of cisplatininduced lesions Fig. 1A . In time, the preferential repair of essential genes will produce regions of the cellular genome that are lesion free (Fig. 1B) . The aim is to measure the rate and extent of repair in specific DNA loci during the early G, phase ofthe cell cycle. To do this, the genomic DNA isolated from the synchronized cells is first digested with restriction enzymes so as to contain the gene sequence of interest and then is incubated with T4 DNA polymerase. In the absence of dNTPs, the T4 DNA polymerase functions as a 3'-5' exonuclease that, starting at a free 3' end, will hydrolyze away one strand until it encounters a blocking lesion (Fig.  1C) . This DNA, single-stranded in the end regions that are free of lesions, is slot-blotted onto a nylon membrane and hybridized against a labeled gene probe (Fig. iD) . The degree of probe binding is a direct measure of the proportion of molecules that are free of cisplatin lesions in the region between the cut site and the distal end of the gene probe sequence. The lack of lesions is due either to a low level of damage to the region or to repair. To establish this assay, the kinetics of hydrolysis and the effect of the position of the probe sequence within the restriction fragment was analyzed.
T4 DNA Polymerase Kinetics. The kinetics of the exonucleolytic activity of T4 DNA polymerase was assessed in A DNA that had been digested with HindIII endonuclease (Fig.  2A) . A 10-min incubation with T4 DNA polymerase resulted (Fig. 2B-D (Fig. 2C) . The cisplatin treatment of the A DNA (total input drug/nucleotide ratio in solution) ranged from 1 bp to 106 bp per cisplatin molecule in solution. If every cisplatin molecule complexes DNA before inactivation by H20, these numbers would represent the amount of bound platinum (3). The actual formation of cisplatin-DNA adducts, for a given input drug/ nucleotide ratio, has been studied by using atomic absorption spectroscopy and found to be less than the theoretical upper limits (3).
After the restricted enzyme-digested phage DNA had been exposed to cisplatin, it was incubated with T4 DNA polymerase, slot-blotted, and hybridized against the denatured 1503-bp probe. The results are shown in Fig. 2B ; the band densities are plotted in Fig. 2D . Fig. 2D shows that the intensity of probe hybridization increases with decreasing cisplatin dose, also for a given dose of cisplatin, the intensity of hybridization increases as the distance between the restriction endonuclease cut cisplatin treatments, yielded a P value of 0.002. This is taken as evidence that differences in DNA platination can be discerned when drug treatment is at these IC50 levels. For the A2780 cell line, the degree of DNA platination. has been assessed previously by atomic absorption spectroscopy (17) .
It was found that the number of adducts increases linearly with cisplatin dose and that, on average, two cisplatin-DNA adducts were formed per 106 bp after a 3 ,uM IC50 exposure.
Effect of Incubation Time with T4 DNA Polymerase on Hybridization Intensities. The intensity of probe hybridization does not appear to be strongly dependent on the incubation time with T4 DNA polymerase. In these studies synchronized cells were treated for 1 hr with 5 puM cisplatin, and DNA was extracted, digested with endonuclease HindIII, and then treated for 10, 20, or 30 min with 1 unit of T4 DNA polymerase. After blotting, the filter was probed with the &globin gene probe, and a 20-min incubation time appeared to give optimal hybridization (Fig. 3B) .
Gene-Specific Repair in Early GI Phase. The positions ofthe human DUG/DHFR and 6-globin probes, within the respective HindIII restriction fragments, are shown in Fig. 4A . To assay for gene-specific repair, the G1 phase-synchronized cells were treated with 5 p.M cisplatin for 1 hr and then allowed to grow in drug-free medium for 0, 2, 3, or 4 hr before the DNA was isolated. The result of blot hybridization of this human DNA against the labeled DUG/DHFR or 8-globin probes after incubation with T4 DNA polymerase is shown in Fig. 4B . At the 0-hr repair time point, the hybridization intensity of the two probes is low (Fig. 4B, top " O" band in I and II). By the 2-hr time point, the hybridization intensity of the DUG/DHFR probe is significantly increased, and this high level ofprobe hybridization is maintained throughout the 3-and 4-hr repair time points. This is indicative of removal of cisplatin lesion from the 5.5-kb sequence coding for DUG and of the bidirectional DUG/DHFR promoter (Fig. 4A) . For the 5-globin gene, the hybridization intensities remained low over the 4 hr of cellular repair studied-consistent with little or no repair. The results of densitometric quantitation, from two independent biological experiments, normalized against the respective unplatinated controls, are shown in Fig. 4C . At the 2-, 3-, and 4-hr repair times, the hybridization intensity of the DUG/DHFR probe was nearly 100% of that of untreated 
DISCUSSION
The assay used here is more sensitive than previous methods for gene-specific repair and allows measurements that use less DNA-damaging agent by 1 or 2 orders of magnitude. This is important if we are to study the biochemical mechanisms underlying the greater drug sensitivity of tumors and the mechanisms by which they acquire resistance. Human A2780 cells that have acquired resistance to cisplatin show increased levels ofglutathione, an intracellular nucleophile that protects cells by complexing reactive cisplatin (8, 27) . At low doses few cisplatin-DNA adducts form; however, at higher doses, when the capacity for cytoplasm detoxification is reached, cisplatin-DNA adducts can start to form in appreciable numbers. This transition may impart a slight nonlinearity in the number of adducts formed around the cisplatin IC50 point (Fig. 3A) .
A limitation with this assay is that we do not yet know which cisplatin lesions are being detected. 19) , shows a marked increase in transcription beginning in early G1 phase, reaching a maximum at the G1/S boundary (30) . The early and sustained transcription of this gene in G1 phase may account for increased levels of repair. The results presented here illustrate the importance of measuring the efficiency ofDNA repair after a physiologically relevant dose of damaging agent and in a defined stage of the cell cycle where gene expression can be determined.
